Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Welcome to the Lexicon Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, 05/13/2025. I will now turn the call over to Lisa DiFrancesco, SVP, Investor Relations and Corporate Communications for ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported fin ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Martin Babler, P ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF NYSE: XBI is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 pandemic, investors now view the sector skeptically. Can battered biotech stocks rebound in 2025? While the broader sector may look scary, some companies are making progre ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Helen Rubinstein - VP-IR and Corporate CommunicationsPaul Berns - Co-Founder, Executive Chairman and Chief Executive OfficerJoshua Pinto - PresidentBill Aurora - Chief Operating & Development OfficerMichael Milligan - CFODouglas Tsao - Managing DirectorBrian Abrahams - MD & Global Sector Head - Health Care ResearchGraig Suvannavejh - Managing DirectorJohn Boyle - Biotechnology Equity Research AssociatePoorna Kann ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubinstein, Vice President of Investor Relations and Communications. Please go ahead. Speaker1 Good afternoon, and thank you fo ...

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweigh ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate in development for prevention of kidney transplant rejection and treatment of autoimmune disorders Cash and cash equivalents of $131.7 million reported as of March 31, 2025; Current cash sufficient to fund o ...

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runw ...